Therapeutic efficiency of IL-2 gene transduced tumor vaccine for head and neck carcinoma
- 1 May 2000
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 152 (2) , 175-185
- https://doi.org/10.1016/s0304-3835(00)00336-0
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells.The Journal of Experimental Medicine, 1993
- Analysis of cytolytic effector cell response in vitro against autologous human tumor cells genetically altered to synthesize interleukin-2Immunology Letters, 1993
- Intratumoral rIL2-based immunotherapy in B16 melanomaJournal of Surgical Research, 1992
- Expression of a functional foreign gene in adult mammalian brain following in Vivo transfer via a herpes simplex virus type 1 defective viral vectorMolecular and Cellular Neuroscience, 1991
- Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity.The Journal of Experimental Medicine, 1990
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- The herpes simplex virus amplicon: A new eucaryotic defective-virus cloning-amplifying vectorCell, 1982
- Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.The Journal of Experimental Medicine, 1982
- Long term culture of tumour-specific cytotoxic T cellsNature, 1977